Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
作者信息
DeFilippis Ersilia M, Butler Javed, Vaduganathan Muthiah
机构信息
From the Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA (E.M.D., M.V.); and Division of Cardiology, Stony Brook University, NY (J.B.).
出版信息
Circ Heart Fail. 2017 Nov;10(11). doi: 10.1161/CIRCHEARTFAILURE.117.004478.
Abstract
摘要
相似文献
1
Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.射血分数降低的新诊断心力衰竭患者植入植入式心脏复律除颤器前的等待期：一个机会之窗。
Circ Heart Fail. 2017 Nov;10(11). doi: 10.1161/CIRCHEARTFAILURE.117.004478.
2
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.评估近期射血分数降低的心力衰竭退伍军人的护理质量。
JAMA Cardiol. 2022 Feb 1;7(2):130-139. doi: 10.1001/jamacardio.2021.4585.
3
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.关于2016年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南的评论
Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1119-1125. doi: 10.1016/j.rec.2016.10.015.
4
Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.在预防心力衰竭猝死方面，神经激素拮抗剂优于植入式心脏复律除颤器。
JACC Heart Fail. 2019 Oct;7(10):902-906. doi: 10.1016/j.jchf.2019.05.013. Epub 2019 Sep 11.
5
Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?心力衰竭伴射血分数降低患者的猝死预防：我们是否仍需要植入式心脏复律除颤器进行一级预防？
Eur J Heart Fail. 2022 Sep;24(9):1460-1466. doi: 10.1002/ejhf.2594. Epub 2022 Jul 16.
6
Management of Chronic Heart Failure with Reduced Ejection Fraction.射血分数降低的慢性心力衰竭的管理。
J Am Board Fam Med. 2024 May-Jun;37(3):364-371. doi: 10.3122/jabfm.2023.230436R1.
7
ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.植入式心脏除颤器仍是预防心力衰竭患者心源性猝死的有效疗法。
JACC Heart Fail. 2019 Oct;7(10):907-910. doi: 10.1016/j.jchf.2019.08.001. Epub 2019 Sep 11.
8
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.心力衰竭住院期间的起始、持续、转换和停药。
JACC Heart Fail. 2019 Jan;7(1):1-12. doi: 10.1016/j.jchf.2018.06.011. Epub 2018 Nov 7.
9
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).在血管紧张素受体脑啡肽酶抑制剂（ARNI）与血管紧张素转换酶抑制剂（ACEI）前瞻性比较以确定对心力衰竭试验（PARADIGM-HF）中全球死亡率和发病率影响的研究中患者的基线特征及治疗情况。
Eur J Heart Fail. 2014 Jul;16(7):817-25. doi: 10.1002/ejhf.115. Epub 2014 Jun 3.
10
The ABCs of managing systolic heart failure: Past, present, and future.管理收缩性心力衰竭的 ABC 法则：过去、现在和未来。
Cleve Clin J Med. 2016 Oct;83(10):753-765. doi: 10.3949/ccjm.83a.16006.
引用本文的文献
1
The Timing for Primary Prevention for ICD in the Current Era of Pharmacotherapy.当前药物治疗时代植入式心律转复除颤器一级预防的时机
Card Fail Rev. 2025 Jun 25;11:e14. doi: 10.15420/cfr.2025.05. eCollection 2025.
2
Pharmacist-led rapid uptitration clinic in heart failure patients with reduced ejection fraction: Our experience within a virtual ward.由药剂师主导的射血分数降低的心力衰竭患者快速滴定诊所：我们在虚拟病房中的经验。
PLOS Digit Health. 2025 Jun 5;4(6):e0000868. doi: 10.1371/journal.pdig.0000868. eCollection 2025 Jun.
3
The Canadian Heart Failure (CAN-HF) Registry: A Canadian Multicentre, Retrospective Study of Outpatients with Heart Failure.加拿大心力衰竭（CAN-HF）注册研究：一项针对加拿大门诊心力衰竭患者的多中心回顾性研究。
CJC Open. 2024 Oct 9;7(1):1-9. doi: 10.1016/j.cjco.2024.09.014. eCollection 2025 Jan.
4
ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing.美国心脏病学会/美国心脏协会/美国超声心动图学会/美国心力衰竭学会/美国心律学会/心血管造影和介入学会/心血管计算机断层扫描学会/心血管磁共振学会2025年植入式心脏复律除颤器、心脏再同步治疗和起搏的合理使用标准
J Am Coll Cardiol. 2025 Mar 25;85(11):1213-1285. doi: 10.1016/j.jacc.2024.11.023. Epub 2025 Jan 13.
5
Status of β-Adrenoceptor Signal Transduction System in Cardiac Hypertrophy and Heart Failure.心脏肥大和心力衰竭中β-肾上腺素能受体信号转导系统的状态
Rev Cardiovasc Med. 2023 Sep 21;24(9):264. doi: 10.31083/j.rcm2409264. eCollection 2023 Sep.
6
Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.治疗持续时间与新发心力衰竭患者心室功能的改善：心力衰竭优化研究。
Eur Heart J. 2024 Aug 9;45(30):2771-2781. doi: 10.1093/eurheartj/ehae334.
7
The State of Heart Failure Care in Canada: Minimal Improvement in Readmissions Over Time Despite an Increased Number of Evidence-Based Therapies.加拿大心力衰竭护理状况：尽管循证疗法数量增加，但再入院率长期以来改善甚微。
CJC Open. 2022 Aug 12;4(8):667-675. doi: 10.1016/j.cjco.2022.04.011. eCollection 2022 Aug.
8
Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care?优化射血分数降低的心力衰竭患者的基础治疗：我们如何将这些研究结果转化为临床治疗？
JACC Basic Transl Sci. 2022 Mar 2;7(5):504-517. doi: 10.1016/j.jacbts.2021.10.018. eCollection 2022 May.
9
A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients.一项评估 AMG 986（一种新型的 Apelin 受体激动剂）在健康受试者和心力衰竭患者中安全性、耐受性、药代动力学和药效学的首次人体研究
Cardiovasc Drugs Ther. 2023 Aug;37(4):743-755. doi: 10.1007/s10557-022-07328-w. Epub 2022 Apr 23.
10
Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy.非缺血性心肌病中心室的逆向重构及其预测因素。
ESC Heart Fail. 2022 Aug;9(4):2070-2083. doi: 10.1002/ehf2.13939. Epub 2022 Apr 18.
本文引用的文献
1
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2017年美国心脏协会/美国心脏病学会/心律学会室性心律失常患者管理和心脏性猝死预防指南：美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会的报告
Circulation. 2018 Sep 25;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549.
2
Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.非缺血性收缩性心力衰竭患者一级预防植入型心律转复除颤器的年龄和结局。
Circulation. 2017 Nov 7;136(19):1772-1780. doi: 10.1161/CIRCULATIONAHA.117.028829. Epub 2017 Sep 6.
3
Declining Risk of Sudden Death in Heart Failure.心力衰竭患者猝死风险降低。
N Engl J Med. 2017 Jul 6;377(1):41-51. doi: 10.1056/NEJMoa1609758.
4
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.因新发诊断或恶化的慢性心力衰竭住院：来自 ASCEND-HF 试验。
J Am Coll Cardiol. 2017 Jun 27;69(25):3029-3039. doi: 10.1016/j.jacc.2017.04.043.
5
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.非缺血性收缩性心力衰竭患者的除颤器植入
N Engl J Med. 2016 Sep 29;375(13):1221-30. doi: 10.1056/NEJMoa1608029. Epub 2016 Aug 27.
6
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南：欧洲心脏病学会（ESC）急性和慢性心力衰竭诊断与治疗特别工作组。由ESC心力衰竭协会（HFA）特别贡献制定。
Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20.
7
Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation.在植入心脏复律除颤器之前使用指南指导的心力衰竭药物治疗。
J Am Coll Cardiol. 2016 Mar 8;67(9):1062-1069. doi: 10.1016/j.jacc.2015.12.046.
8
Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).可穿戴式心脏除颤器在高危心脏患者中的应用：来自前瞻性可穿戴式心脏除颤器（WEARIT-II 注册研究）患者使用登记数据库的数据。
Circulation. 2015 Oct 27;132(17):1613-9. doi: 10.1161/CIRCULATIONAHA.115.015677. Epub 2015 Aug 27.
9
Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.瑞马唑仑对急性心力衰竭患者死亡方式的影响：RELAX-AHF 研究结果。
J Am Coll Cardiol. 2014 Oct 14;64(15):1591-8. doi: 10.1016/j.jacc.2014.05.071.
10
ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013年植入式心脏复律除颤器及心脏再同步治疗的合理应用标准：美国心脏病学基金会合理应用标准工作组、心律学会、美国心脏协会、美国超声心动图学会、美国心力衰竭学会、心血管造影和介入学会、心血管计算机断层扫描学会以及心血管磁共振学会的报告
Heart Rhythm. 2013 Apr;10(4):e11-58. doi: 10.1016/j.hrthm.2013.01.008. Epub 2013 Mar 7.
Zotero 插件